A commercial medical device manufacturer with an established global presence sought regulatory guidance while preparing a new web-based software platform supporting the radiology market. The company generated more than $100 million in annual revenue and marketed products in over 40 countries.
To accelerate development, the company leveraged artificial intelligence to generate both software code and supporting documentation for a web-based medical device intended for FDA 510(k) clearance. As AI-assisted software development becomes more common, the company wanted to understand FDA expectations before moving forward with its submission.
Challenge:
The client believed AI-enabled development had significantly reduced the time and cost required to bring the product to market. However, uncertainty remained regarding:
- Whether the use of AI during software development required disclosure in the FDA submission.
- Whether AI-generated documentation would satisfy FDA expectations.
- What additional software lifecycle documentation and design controls would be necessary for a successful 510(k).
Without clear regulatory guidance, internal teams were spending considerable time debating FDA expectations, creating delays in decision-making and uncertainty around commercialization timelines.
Approach
AlvaMed performed a regulatory and software quality assessment to evaluate the client’s readiness for a 510(k) submission.
The engagement included:
- Reviewing the software development approach and AI-assisted development process.
- Assessing the completeness of the software lifecycle documentation against FDA expectations.
- Identifying documentation gaps required to support a compliant submission.
- Providing regulatory interpretation regarding FDA expectations for AI-assisted software development.
- Delivering a detailed gap assessment report outlining required documentation and recommended next steps.
- Presenting the findings to executive leadership to align technical and business stakeholders on the regulatory path forward.
AlvaMed also clarified an important regulatory distinction: because AI was used to accelerate software development and not as part of the product’s intended functionality or machine learning capabilities – it did not require separate disclosure as an AI-enabled medical device feature. However, the underlying software development documentation still needed to meet FDA expectations regardless of how the code was generated.
Results
AlvaMed helped the client replace uncertainty with a clear regulatory strategy that balanced innovation with compliance.
The engagement resulted in:
- A well-defined roadmap for completing FDA-ready software documentation.
- Reduced regulatory uncertainty regarding AI-assisted software development.
- Alignment between engineering, business, and executive leadership on realistic commercialization timelines.
- Identification of documentation deficiencies before submission, reducing regulatory risk.
- Greater confidence that the future 510(k) submission would be supported by appropriate software lifecycle documentation and design controls.
The project also reinforced an important industry lesson: while AI can significantly accelerate software development, it does not eliminate the need for rigorous documentation, design controls, and software quality activities expected by regulators.
Key Services Provided
- FDA 510(k) regulatory strategy
- Software quality assurance consulting
- Software documentation gap assessment
- AI regulatory interpretation
- Software lifecycle documentation review
- Executive regulatory advisory support
Key Takeaway
AI is changing how medical device software is developed, but it is not changing FDA’s expectations for demonstrating that software is safe, effective, and developed under appropriate design controls. By providing practical regulatory guidance and identifying documentation gaps early, AlvaMed helped the client preserve the efficiencies gained through AI-assisted development while establishing a clear path toward a successful FDA submission.
